EntityRisk announced that Jeffrey B. Kindler and Frank D’Amelio have led a Series A investment in the company and have been appointed to EntityRisk’s board of directors.
Prof. Andy Whiting, Nevrargenics, responds to the lack of translational funding for the biotech industry, and what more needs to be done to close the gap between drug development and clinical trials.
Last Thursday, chancellor Jeremy Hunt announced new measures for smoother medicine approvals in the UK, increased support for R&D, and a simplified tax system for SMEs. UK biotech company, Nevrargenics shared its position on the 2023 Budget.
Emma Palmer Foster, director of Discovery Park Ventures, shares her advice to early stage life sciences companies on how to improve their chances of gaining funding.
Co-founded by the cancer institute Gustave Roussy, Paris-Saclay University and the French company Clevexel Pharma, Graegis Pharmaceuticals plans to start proof-of-concept clinical trials in 2023 in the prevention of radiation-induced dermatitis.
Martino Picardo, chairman of Discovery Park and a director of Discovery Park Ventures, explores the funding barriers preventing the growth of female-led life sciences companies.
Sally-Anne Whybrow, healthcare business development manager, Siemens Financial Services, UK examines how smart financing can help CROs invest in financially-sustainable technology.
Following on from their recent partnership with Israel Biotech Fund (IBF), EPM caught up with Lonza's Pnina Weitz on the importance of early-stage support for emerging companies, and how robust strategies early on can pave a way to commercialisation.
Adrienne Rivlin, Partner, and Jess Sharpe, Associate, at L.E.K. Consulting assess the rise in investment seen within the psychedelics market for mental health.
EPM speaks to Sophie Walton, group director of Academic Engagement, CPI, to learn about the Northern BioAccelerator Partnership, which was set up to stimulate investment in the North East’s bioscience sector.
